Wada T, Furuichi K, Segawa-Takaeda C, Shimizu M, Sakai N, Takeda S I, Takasawa K, Kida H, Kobayashi K I, Mukaida N, Ohmoto Y, Matsushima K, Yokoyama H
First Department of Internal Medicine, School of Medicine, Kanazawa University, Japan.
Kidney Int. 1999 Sep;56(3):995-1003. doi: 10.1046/j.1523-1755.1999.00646.x.
The precise molecular mechanisms of macrophage (Mphi) recruitment and activation in crescentic glomerulonephritis remain to be investigated. We hypothesized that locally produced macrophage inflammatory protein (MIP)-1alpha and monocyte chemoattractant protein (MCP)-1 via the chemokine receptors participate in the pathophysiology of human crescentic glomerulonephritis by recruiting and activating Mphi.
We investigated the levels of MIP-1alpha and MCP-1 by enzyme-linked immunosorbent assay (ELISA) in 20 healthy subjects, 20 patients with crescentic glomerulonephritis, and 41 control patients with various other renal diseases. The presence of MIP-1alpha, MCP-1, and the cognate chemokine receptor for MIP-1alpha, CCR5, in the diseased kidneys was evaluated by immunohistochemical and in situ hybridization analyses.
MIP-1alpha-positive cells were mainly detected in crescentic lesions, whereas MCP-1 was mainly in the interstitium. In addition, we detected CCR5-positive cells in diseased glomeruli and interstitium. Urinary MIP-1alpha was detected in crescentic glomerulonephritis, even though it was below detectable levels in healthy subjects and in patients with other renal diseases without crescents. Urinary MIP-1alpha levels in the patients with crescentic glomerulonephritis were well correlated with the percentage of cellular crescents and the number of CD68-positive infiltrating cells and CCR5-positive cells in the glomeruli. However, urinary MCP-1 levels were well correlated with the percentage of both total crescents and fibrocellular/fibrous crescents and the number of CD68-positive infiltrating cells in the interstitium. Moreover, elevated urinary levels of both MIP-1alpha and MCP-1 dramatically decreased during glucocorticoid therapy-induced convalescence.
These observations suggest that locally produced MIP-1alpha may be involved in the development of cellular crescents in the acute phase via CCR5 and that MCP-1 may be involved mainly in the development of interstitial lesions in the chronic phase when fibrocellular/fibrous crescents are present, possibly through Mphi recruitment and activation.
新月体性肾小球肾炎中巨噬细胞(Mphi)募集和激活的确切分子机制仍有待研究。我们推测,通过趋化因子受体在局部产生的巨噬细胞炎性蛋白(MIP)-1α和单核细胞趋化蛋白(MCP)-1通过募集和激活Mphi参与人类新月体性肾小球肾炎的病理生理过程。
我们采用酶联免疫吸附测定(ELISA)法检测了20名健康受试者、20例新月体性肾小球肾炎患者以及41例其他各种肾脏疾病对照患者体内MIP-1α和MCP-1的水平。通过免疫组织化学和原位杂交分析评估患病肾脏中MIP-1α、MCP-1以及MIP-1α的同源趋化因子受体CCR5的存在情况。
MIP-1α阳性细胞主要在新月体病变中检测到,而MCP-1主要存在于间质中。此外,我们在患病的肾小球和间质中检测到CCR5阳性细胞。在新月体性肾小球肾炎患者尿液中检测到MIP-1α,尽管在健康受试者和无新月体的其他肾脏疾病患者中其水平低于可检测范围。新月体性肾小球肾炎患者尿液中MIP-1α水平与细胞新月体百分比以及肾小球中CD68阳性浸润细胞和CCR5阳性细胞数量密切相关。然而,尿液中MCP-1水平与总新月体以及纤维细胞性/纤维性新月体百分比和间质中CD68阳性浸润细胞数量密切相关。此外,在糖皮质激素治疗诱导的恢复期,尿液中MIP-1α和MCP-1水平均显著下降。
这些观察结果表明,局部产生的MIP-1α可能在急性期通过CCR5参与细胞新月体的形成,而MCP-1可能主要在存在纤维细胞性/纤维性新月体的慢性期通过Mphi募集和激活参与间质病变的形成。